The state of California currently has 19 active clinical trials seeking participants for NASH - Nonalcoholic Steatohepatitis research studies. These trials are conducted in various cities, including Los Angeles, San Francisco, San Diego and Sacramento.
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Non-Alcoholic Steatohepatitis (NASH) in Adult Participants at Increased Genetic Risk for This Condition
Recruiting
This study is researching an investigational drug called ALN-HSD (called "study drug"). This study is focused on participants who are known to have non-alcoholic steatohepatitis (NASH). NASH is a form of non-alcoholic fatty liver disease (NAFLD). Recently, the name metabolic dysfunction associated steatohepatitis (MASH) has been introduced to replace NASH and metabolic dysfunction-associated steatotic liver disease (MASLD) to replace NAFLD. NASH occurs when fat builds up in liver cells, damaging... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/13/2024
Locations: San Fernando Valley Health Institute, Canoga Park, California +10 locations
Conditions: Non-alcoholic Steatohepatitis (NASH), Metabolic Dysfunction Associated Steatohepatitis (MASH)
Androgens and NAFLD Longitudinal Cohort Study
Recruiting
The researchers want to learn how androgens, a type of sex hormone, might affect nonalcoholic fatty liver (NAFLD) in young women over time. NAFLD happens when fat builds up in the liver which can cause damage to the liver such as inflammation or scarring. Young women with a condition called polycystic ovary syndrome (PCOS) have a high risk for NAFLD, and they often have high androgen levels too. So the researchers are recruiting young women with PCOS as well as those without PCOS, and will comp... Read More
Gender:
Female
Ages:
Between 18 years and 40 years
Trial Updated:
06/12/2024
Locations: University of California San Francisco, San Francisco, California
Conditions: PCOS, NAFLD, NASH
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight
Recruiting
This study is open to adults who are at least 18 years old and have presumed or confirmed NASH together with overweight or obesity and a body mass index (BMI) of 30 kg/m² or more, or a BMI of 27 kg/m² and at least one weight-related health problem. People with a history of other chronic liver diseases cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps people living with obesity or overweight and a confirmed or presumed liver di... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Velocity Clinical Research, Gardena, California +1 locations
Conditions: Obesity, Non-Alcoholic SteatoHepatitis (NASH)
Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis
Recruiting
Participants meeting study entry criteria are randomized with equal probability to one of two study groups: (1) Lifestyle modification or (2) Vertical Sleeve Gastrectomy (VSG) with Iifestyle modification, followed for 12 months. The primary goal for the trial is to determine if the investigators can recruit, randomize, and retain participants to perform invasive and non-invasive measurements of NASH and fibrosis, deliver lifestyle modification and demonstrate the safety of VSG. The investigators... Read More
Gender:
All
Ages:
Between 30 years and 70 years
Trial Updated:
06/07/2024
Locations: University of San Fransisco, San Francisco, California
Conditions: NASH - Nonalcoholic Steatohepatitis
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Recruiting
The study will assess the efficacy and safety of 2 dose regimens of pegozafermin for the treatment of liver fibrosis stage 2 or 3 in adult participants with MASH (previously known as nonalcoholic steatohepatitis [NASH]).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/07/2024
Locations: 89bio Clinical Study Site, Fountain Valley, California +7 locations
Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Recruiting
The aim of this study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASH/MASH and NAFLD/MASLD.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/04/2024
Locations: Akero Clinical Study Site, Chula Vista, California +13 locations
Conditions: NASH/MASH, NAFLD/MASLD
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Recruiting
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/04/2024
Locations: Akero Clinical Study Site, Chula Vista, California +13 locations
Conditions: NASH With Fibrosis, MASH With Fibrosis
Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Recruiting
The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH [previously known as nonalcoholic steatohepatitis, NASH]).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/01/2024
Locations: 89bio Clinical Study Site, Rialto, California
Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
Recruiting
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis (MONARCH)
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/23/2024
Locations: Site #378, Huntington Park, California +5 locations
Conditions: Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH)
Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) (IMPACT Trial)
Recruiting
Purpose of this study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/14/2024
Locations: Altimmune Clinical Study Site, North Hollywood, California +1 locations
Conditions: Non-Alcoholic Steatohepatitis (NASH)
Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects
Recruiting
This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
05/13/2024
Locations: NAFLD Research Center - Altman Clinical and Translational Research Institute, La Jolla, California +3 locations
Conditions: NASH - Nonalcoholic Steatohepatitis
Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis
Recruiting
A study to investigate the use of combination therapy with two investigational products for the treatment of adult patients with Nonalcoholic steatohepatitis (NASH).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/07/2024
Locations: Velocity Clinical Research, Huntington Park, California +4 locations
Conditions: NASH